Lin Yung-Kai, Lin Yung-Hsiang, Chiang Chi-Fu, Yeh Tsung-Ming, Shih Wen-Ling
Institute of Food Safety and Risk Management, Department of Food Science, National Taiwan Ocean University, Keelung, Taiwan.
Research & Design Center, TCI Co., Ltd., Taipei, Taiwan.
3 Biotech. 2022 Dec;12(12):341. doi: 10.1007/s13205-022-03356-3. Epub 2022 Nov 4.
The multiple probiotic characteristics of strain TCI904 isolated in this study from natural fermented milk were investigated using a mouse model. TCI904 was identified as subsp. (LDB, a well-known lactic acid starter bacterium found in yogurt. TCI904 exhibited an outstanding pancreatic lipase inhibition activity among several strains of lactic acid bacteria in vitro Its in vivo effects were further studied. In a comparison of mice fed a high-fat diet (HFD) and those fed a HFD combined with TCI904 for 9 weeks, differences were observed in various aspects of health, and the adverse effects of a HFD were prevented in the latter group. TCI904 effectively prevented fat and body weight accumulation without reducing food intake; it also modulated innate immunity and increased the level of IgA in feces, reversing the increased blood sugar and insulin levels and attenuated the hyperlipidemia caused by a HFD. Based on biochemical test data, compared with the HFD group, a HFD combined with TCI904 induced significant lowering of insulin resistance indicator, homeostasis model assessment-insulin resistance (HOMA-IR) and atherogenic indices of plasma (AIP), the atherogenic coefficient (AC) and cardiac risk ratio (CRR) and increased the cardioprotective index (CPI). In addition, the administration of TCI904 alleviated mood disorders caused by a HFD. Taking the recommended human dose of TCI904 did not affect the liver or kidney function, indicating that TCI904 has sufficient in vivo safety. Taken together, the results of the present study contributed towards validation of the probiotic benefits of lactic acid starter microflora. Orally taken TCI904 exhibited positive immune- and metabolic-modulating, and anxiolytic properties, especially in HFD-induced obesity.
The online version contains supplementary material available at 10.1007/s13205-022-03356-3.
本研究从天然发酵乳中分离出的菌株TCI904的多种益生菌特性,采用小鼠模型进行了研究。TCI904被鉴定为亚种。(LDB,一种在酸奶中发现的著名乳酸发酵起始菌。TCI904在体外几种乳酸菌菌株中表现出出色的胰脂肪酶抑制活性。对其体内作用进行了进一步研究。在对喂食高脂饮食(HFD)的小鼠和喂食HFD并联合TCI904 9周的小鼠进行比较时,在健康的各个方面观察到了差异,后一组预防了HFD的不良影响。TCI904有效地预防了脂肪和体重增加,而不减少食物摄入量;它还调节先天免疫并增加粪便中IgA的水平,逆转了血糖和胰岛素水平的升高,并减轻了HFD引起的高脂血症。根据生化测试数据,与HFD组相比,HFD联合TCI904可显著降低胰岛素抵抗指标、稳态模型评估-胰岛素抵抗(HOMA-IR)和血浆致动脉粥样硬化指数(AIP)、动脉粥样硬化系数(AC)和心脏风险比(CRR),并增加心脏保护指数(CPI)。此外,给予TCI904可缓解HFD引起的情绪障碍。服用推荐的人体剂量的TCI904不会影响肝脏或肾脏功能,表明TCI904在体内具有足够的安全性。综上所述,本研究结果有助于验证乳酸发酵起始微生物群的益生菌益处。口服TCI904表现出积极的免疫调节、代谢调节和抗焦虑特性,尤其是在HFD诱导的肥胖中。
在线版本包含可在10.1007/s13205-022-03356-3获取的补充材料。